ARGEN is a highly efficient instrument for quickly evaluating the stability and viability of therapeutic proteins, peptides, and biopolymers. The tool employs a multi-stressor testing platform based ...

When therapeutic proteins form aggregates, they can limit clinical effectiveness and possibly provoke a serious immunogenic response. Thermostability screening by way of a temperature ramp is a ...

Advances in monoclonal antibody (mAb) technology have revolutionized the field of biological research. With applications in both research and therapeutics, mAb development is one of the fastest ...

Monoclonal antibodies require rigorous purification to help remove aggregates and impurities that can compromise safety and efficacy. As these molecules become more complex, purification processes ...

Monoclonal antibodies are highly specific for their antigen and have a well-characterized structure, making them ideal for use as antibody therapeutics. 5 Each mAb, composed of two heavy and two light ...

Purity, aggregation state, and target binding are critical quality requirements that need to be monitored throughout the antibody development cycle as they impact product efficacy and safety. Yet, ...

Next-generation monoclonal antibodies (mAbs), including bispecifics and multimerized formats, present increasingly complex purification challenges. Unique structural features and elevated impurity ...

One longstanding and ongoing challenge for bioprocessors is the removal of host-cell proteins (HCPs). “The entire HCP field has taken off in the last several years and numerous groups have contributed ...